How does a startup compete with the likes of Eli Lilly and Novo Nordisk in the rapidly evolving field of weight loss drugs? And how did a major telemedicine company fall flat after its pandemic-induced rise?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We bring on biotech veteran Clive Meanwell to discuss his new obesity startup, Metsera, and running head-to-head trials against Wegovy and Zepbound. We also dissect how Teledoc CEO Jason Gorevic parted ways with the company after spending 15 years building the telemedicine field.
Click this link for the original source of this article.
Author: Allison DeAngelis and Adam Feuerstein
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.